Becton, Dickinson and Co (NYSE:BDXB.PFD)
$ 48.16 0.66 (1.39%) Market Cap: - Enterprise Value: - PE Ratio: 48.87 PB Ratio: 2.65 GF Score: 79/100

Becton Dickinson and Co at Wells Fargo Healthcare Conference Transcript

Sep 07, 2022 / 04:30PM GMT
Release Date Price: $50.86 (+0.85%)
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

Can everyone hear me okay? Seems like it. Good. All right. Well, good afternoon, everyone. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. And I'm really pleased to introduce our keynote speaker today, Tom Polen, the CEO of Becton, Dickinson. Also joining Tom is Chris DelOrefice, BD's CFO.

I asked Tom to be our keynote speaker today because BD is one of the largest and most diversified medical device companies in the world, which provides the company with unique insights on the macro environment as well as the medical device landscape. In addition, BD has been very successful navigating this challenging environment, so I thought investors would be interested to hear what the company is saying.

For those of you who don't know Tom, Tom has been the CEO of BD since January 2020. Before that, he was President and Chief Operating Officer of BD, where he led the $24 billion Bard acquisition. Tom has over 25 years of medical device experience. And for those of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot